

Table of Contents

| | |
|-------------------------------------------------------------------------------------------------------------|-----------|
| Author Acknowledgments..... | ix |
| SECTION I: Risk Management Regulations | 1 |
| Chapter 1 Risk Management Regulations in the US..... | 3 |
| <i>Brande Yaist, MS; Debra Porter, MS; Debashish Dey, MD, PhD, MPH; and Nayan Achayara MBBS, MRCP, MFPM</i> | |
| Chapter 2 Regulations Related to Risk Management in Japan..... | 39 |
| <i>Yong Huang, MD, PhD; Krishna Babadursingh, MD, FRCS, MBA, LLB, FFPM; and Hiroshi Nakane</i> | |
| Chapter 3 European Experience with Additional Risk Minimization and its Impact on Benefit-Risk..... | 49 |
| <i>Darin Oppenheimer DRSc, FRAPS, RAC and George Cusatis MS, RAC</i> | |
| Chapter 4 Risk Management of Medicines and Biologicals in Australia..... | 59 |
| <i>Judy Bingham, MHA, GAICD</i> | |
| Chapter 5 Risk Management in Canada..... | 71 |
| <i>David Konadu, MSc, MASc</i> | |
| SECTION II: Benefit-Risk Management Principles and Practices | 83 |
| Chapter 6 The Impact of Preclinical Planning and Study Outcome on the Risk Management of Biologicals..... | 85 |
| <i>Michael Engwall, DVM, PhD, DSP</i> | |
| Chapter 7 Risk Management in Medical Devices and Artificial Intelligence..... | 99 |
| <i>Leo Hovestadt, MSc</i> | |
| Chapter 8 Quality Risk Management: A Gateway to Quality by Design..... | 121 |
| <i>Beat Widler, PhD, dipl. pharm. med., and Peter Schiemann, PhD, MBA</i> | |
| Chapter 9 Quality Management Systems for Medical Devices | 133 |
| <i>Russ Roberson, PhD, MBA, MScME, BScAgE</i> | |
| Chapter 10 Risk Management Principles and Processes for OTC Medicines..... | 153 |
| <i>Michael Steinbuch, PhD, FISPE, Matthew Francis, MS, PhD, and Andrej Miotk, PhD</i> | |

| | | |
|--------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Chapter 11 | Clinical Evaluation Reports | 165 |
| | <i>Leo Hovestadt, MSc</i> | |
| Chapter 12 | EU Postauthorization Safety Studies, US Postmarket Requirement, and US Postmarket Commitment | 181 |
| | <i>Tara Isherwood, MSc, BSc (Hons) and Mark Heinemann, BSc</i> | |
| Chapter 13 | Minimizing and Monitoring Safety | 199 |
| | <i>Karin de Haart, MSc, Nadja Merkusheva, MD, Bernadette Dwan, BSc, Mpharm, MPSI, Lisette Hoogendoorn, PhD, and Priscilla Velentgas, PhD</i> | |
| Chapter 14 | Use of Pregnancy Exposure Registries and Outcomes Studies for Risk Management ... | 213 |
| | <i>Jessica D. Albano, PhD, MPH, Angie Graves, MBA, MLS(ASCP), Sara Ephross, PhD, Brian Buysse, PhD and Tara Isherwood, MSc</i> | |
| Chapter 15 | Clinical Evidence and Acceptable Benefit–Risk Evaluation | 225 |
| | <i>Leo Hovestadt, MSc</i> | |
| Chapter 16 | Benefit-Risk Assessment: Art or Science? | 239 |
| | <i>Mariette Boerstoeel-Streefland, MD, MSc, MBA</i> | |
| Chapter 17 | Risk Management in the Future: Expanding the Use of Electronic Health Records in Drug Development | 249 |
| | <i>Tjeerd–Pieter van Staa, MD, MSc, MA, PhD</i> | |
| SECTION III: Case Studies in Risk Assessment and Management | | 257 |
| Chapter 18 | Postmarket Pharmacoepidemiology Database Study Development to Evaluate Long-Term Drug Safety—An Example, Prolia | 259 |
| | <i>Fei Xue, MD, MSC, ScD</i> | |
| Chapter 19 | EHR Use for Stimulated Reporting of Adverse Drug Events | 269 |
| | <i>Angela Walker, MD and Richard Loomis, MD</i> | |
| Chapter 20 | RM During Peri-Approval Process: A Case Study of Actonel | 283 |
| | <i>Bruce R. DeMark, PhD</i> | |
| SECTION IV: Risk Communication, Dissemination, and Implementation | | 307 |
| Chapter 21 | Social Science Theory as a Framework for Designing and Evaluating Pharmaceutical Risk Management Dissemination and Implementation Strategies | 309 |
| | <i>Elaine H. Morrato, DrPH, MPH, CPH</i> | |
| Chapter 22 | Using Mixed Methods to Evaluate Therapeutic Risk Minimization Programs: An Introduction and Case Study | 333 |
| | <i>Meredith Y. Smith, PhD, MPA, FISPE</i> | |

SECTION V: REMS343

| | |
|------------|-------------------------------------------------------------------------------------|
| Chapter 23 | Developing, Implementing, and Operating REMS Programs345 |
| | <i>Paul Sheehan, MSJ, BSc, Lindsay Crampton, BSc, and Jemma Contreras, PhD, BSc</i> |

Figures

| | |
|--------------|-----------------------------------------------------------------------------------------------------------------------------------|
| Figure 1-1. | Overview of Risk Management5 |
| Figure 1-2. | Safety Focus Throughout a Product's Lifecycle6 |
| Figure 1-3. | Comparison of Monitoring and Control for a Traditional Product Launch versus a Product Launched With a Risk Management Plan.....7 |
| Figure 1-4. | US Drug Regulation Advancements.....19 |
| Figure 1-5. | Distribution of Combinations of Risk Management Elements Required by FDA (based on 2022 Active REMS Elements Combinations).....22 |
| Figure 1-6. | Comparison of Combination of Active REMS Elements 2008–10 and 2011.....23 |
| Figure 1-7. | Assessment of Effectiveness of REMS Medication Guide.....25 |
| Figure 1-8. | Example of a REMS Assessment Implementation Timeline.....27 |
| Figure 1-9. | FDA Postmarket Commitments and Requirements by Year29 |
| Figure 1-10. | FDA Postmarket Safety Requirements by Type.....30 |
| Figure 1-11. | History of the Sentinel Initiative.....32 |
| Figure 1-12. | Overview of the Mini-Sentinel Safety Question Evaluation Process33 |
| Figure 2-1. | Postapproval Surveillance System42 |
| Figure 2-2. | Timeline for Postapproval Surveillance System*43 |
| Figure 3-1. | Process for Developing a Risk Minimization Plan54 |
| Figure 3-2. | Sample Benefit-Risk Profile Template.....55 |
| Figure 3-3. | Benefit-Risk and Risk Minimization Process56 |
| Figure 4-1. | Risk Management Overview (AS/NZA ISO 31000:2018).....60 |
| Figure 5-1. | Risk Management Process77 |
| Figure 7-1. | Risk Management Process Steps.....102 |
| Figure 7-2. | Risk Management Flow Using Hazard Analysis Technique.....103 |
| Figure 7-3. | ISO 14971 Integration with Regulations and Standards111 |
| Figure 7-4. | ISO 13485 Activities Related to Risk Management.....113 |
| Figure 7-5. | Medical Device Use116 |
| Figure 7-6. | Relation Between ISO 14971 and IEC 62366-1117 |
| Figure 8-1. | Failure Mode and Effect Analysis (FMEA) Cycle124 |
| Figure 8-2. | Three-Step RPN-based Risk Evaluation127 |
| Figure 8-3. | Example of QRM in Action128 |
| Figure 9-1. | Example of FDA Medical Device Classifications134 |
| Figure 9-2. | Seven Risks of Medical Devices.....139 |
| Figure 9-3. | The Risk Cycle141 |
| Figure 9-4. | Generic SWEATT Model.....143 |
| Figure 9-5. | Software Product Design SWEATT Model: Before147 |
| Figure 9-6. | Software Product Design SWEATT Model: After148 |
| Figure 9-7. | Product Risk SWEATT Model.....150 |
| Figure 10-1. | Shifting Safety Focus as Medicines Mature.....154 |
| Figure 11-1. | Clinical Investigation Registration Requirements.....175 |
| Figure 12-1. | Noninterventional Postauthorization Safety Study Requirements.....185 |
| Figure 12-2. | Endorsement for Single-Country Postauthorization Safety Studies Procedure.....189 |
| Figure 12-3. | Module I Requirement Compliance Approach.....192 |
| Figure 12-4. | Activities Impacting PV System Quality193 |
| Figure 13-1. | Asking the Right Questions206 |

| | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| Figure 15-1. MDR Needs to Set a High Standard of Quality and Safety..... | 226 |
| Figure 15-2. MDR Clinical Evidence Objectives Per Device Life Cycle Phase | 227 |
| Figure 15-3. Valid Clinical Association | 230 |
| Figure 15-4. Technical Performance..... | 231 |
| Figure 15-5. Clinical Performance..... | 231 |
| Figure 15-6. Clinical Evidence Example for Radiation Treatment Planning | 232 |
| Figure 15-7. Endpoints for Clinical Evidence..... | 233 |
| Figure 15-8. MDR Requirements Related to Endpoints for Clinical Evidence..... | 234 |
| Figure 15-9. Acceptable Benefit-Risk | 237 |
| Figure 18-1. Time at Risk Estimate Based on On-Treatment and Post-Treatment Period for a Patient Receiving One Dose of Bisphosphonate Before Receiving One Dose of Prolia | 263 |
| Figure 19-1. PASP Clinical Decision Support Notification in the Practice Fusion EHR..... | 276 |
| Figure 19-2. Screenshot of Safety Surveillance Interface in Practice Fusion EHR | 277 |
| Figure 22-1. Types of Outcomes in RM Program Evaluation Research by Data Collection Method (Quantitative Versus Qualitative) (per GVP Module XVI Revision 3)..... | 334 |
| Figure 22-2. An Embedded Mixed Methods Design with Complementarity Model to Evaluate the Effectiveness of the Risk Minimization Program for Product C. | 337 |
| Figure 23-1. Key Milestones in Developing, Implementing, and Operating a REMS: Brand Drug | 348 |
| Figure 23-2. Key Milestones in Developing, Implementing, and Operating a REMS: Generic Drugs..... | 349 |
| Figure 23-3. FDA Engagement Timeline | 350 |
| Figure 23-4. FDA Engagement for ANDA REMS..... | 351 |
| Figure 23-5. Services Involved in a Typical ETASU REMS..... | 352 |
| Figure 23-6. Services Involved in a Typical ETASU REMS: Example | 353 |
| Figure 23-7. Integration of REMS with Other Launch Activities..... | 354 |
| Figure 23-8. REMS Assessment Categories | 355 |

Tables

| | |
|--------------------------------------------------------------------------------------------------------|-----|
| Table 1-1. Timeline of US Drug Regulation Advancements | 11 |
| Table 1-2. Example Framework of FDA Risk Management Guidance and Regulations | 13 |
| Table 1-3. Legacy Pharmaceutical Products Deemed to Have a REMS Following FDAAA Implementation..... | 20 |
| Table 1-4. Examples of Triggers for FDA Requiring a REMS..... | 21 |
| Table 1-5. Example of a REMS Implementation Plan | 28 |
| Table 1-6. FDA Benefit-Risk Framework..... | 35 |
| Table 2-1. Regulatory Reporting of ICSRs for Investigational drugs | 40 |
| Table 2-2. Foreign Safety Measures Report and Research Report..... | 41 |
| Table 2-3. Regulatory Reporting of Postmarket Adverse Drug Reactions in Japan..... | 44 |
| Table 2-4. Regulatory Reporting of Postmarket Infections in Japan..... | 45 |
| Table 4-1. Reporting Requirements for Biologicals | 65 |
| Table 6-1. Summary Elements of an ETLA..... | 86 |
| Table 6-2. Factors Affecting the Safety Margin Calculations for FIH | 92 |
| Table 6-3. Hypothetical Risk Management Strategy for GLP-1 Agonist Biotherapeutics..... | 93 |
| Table 7-1. Contents of ISO 14971:2019..... | 100 |
| Table 7-2. Hazard Analysis Table | 104 |
| Table 7-3. Risk Management File Contents..... | 105 |
| Table 7-4. Example Severity Levels | 107 |
| Table 7-5. Example Probability Of Occurrence Levels..... | 107 |
| Table 7-6. Risk Evaluation Matrix..... | 108 |

| | | |
|--------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| Table 7-7. | Example Acceptability Legend | 108 |
| Table 8-1. | Traditional Quality Management vs. QRM Approach | 129 |
| Table 10-1. | Examples of Risk Mitigation and Monitoring | 160 |
| Table 11-1. | Clinical Evidence Premarket Documentation Requirements | 167 |
| Table 11-2. | Clinical Evidence Postmarket Documentation Requirements | 167 |
| Table 11-3. | Clinical Evidence Element General Safety and Performance Requirements | 167 |
| Table 11-4. | Clinical Evidence Element not in General Safety and Performance Requirements | 172 |
| Table 11-5. | Clinical Evidence Elements for Medical Device Software | 173 |
| Table 11-6. | Clinical Development Plan with R-IDEAL Endpoints | 176 |
| Table 12-1. | Categories of PASS | 184 |
| Table 12-2. | Summary of Applicable Regulatory Requirements for PASS Conducted in the EU | 184 |
| Table 12-3. | Regulatory Requirements for Noninterventional PASS | 187 |
| Table 12-4. | GVP Module I: Purpose and Applicability to PASS | 190 |
| Table 12-5. | GVP Modules II, IV, V and VI: Purposes and Applicability to PASS | 191 |
| Table 12-6. | Management of Adverse Events for NI PAS with a Design Based on Primary Data Collection | 194 |
| Table 12-7. | Obligations to Consider for Conduct of US PMS | 195 |
| Table 15-1. | Medical Device Clinical Evidence Requirements | 228 |
| Table 15-2. | Medical Device Software Clinical Evidence Requirements | 229 |
| Table 15-3. | Medical Device Clinical Evidence Requirements for Quality and Quantity | 230 |
| Table 19-1. | Adverse Drug Event Detection and Reporting Methods | 271 |
| Table 19-2. | Comparison of Current and Proposed Programs | 278 |
| Table 20-1. | Combined Osteoporosis Treatment and Prevention Trials including Hip Fracture Trials | 284 |
| Table 20-2. | Lung Cancer in Risedronate Phase III PMO/CIO and HIP Fracture Trials | 285 |
| Table 20-3. | Distribution of Cancer Cases by COSTART: Ten Combined Risedronate Trials | 286 |
| Table 20-4. | GI Cancer in Combined Risedronate Phase III PMO/CIO and Hip Fracture Trials | 287 |
| Table 20-5. | FDA Statistical Analysis of Lung Cancer by Smoking History, Age, and Risedronate Dose in Risedronate Clinical Studies | 287 |
| Table 20-6. | Observed to Expected Lung Cancer Cases in Combined Risedronate Studies Based on the SEER Database (1988-1992) for US White Women | 288 |
| Table 20-7. | Distribution of Lung Cancer Based on Best Available Evidence | 289 |
| Table 20-8. | Categorization of Lung Cancer Data | 290 |
| Table 20-9. | Lung Cancers Excluding Cases < 6 Months After Dosing | 290 |
| Table 20-10. | Time of Diagnosis for 59 Cases of Lung Cancer | 291 |
| Table 20-11. | Incidence of Lung Cancer Based on 1,000 Person-Years of Observation | 292 |
| Table 20-12. | Cancer Cases by Site | 294 |
| Table 20-13. | Anticipated Deaths Due to Lung Cancer in Mortality Follow-Up Studies RVN, RON, and RHN | 295 |
| Table 20-14. | Patient-Years of Follow-up for RON009393, RVN008993, and RHN009193 | 296 |
| Table 20-15. | “On-Study” Mortality Studies RON009393, RVN008993, and RHN009193 | 297 |
| Table 20-16. | Estimated Mortality Due to Lung Cancer (Assumes RR* of 1.0 During “Off-Study” Follow-up of Non-incident Lung Cancer Cases, Studies RON009393, RVN008993, and RHN009193) | 298 |
| Table 20-17. | Estimated Mortality Due to Lung Cancer (Assumes RR* of 2.0 during “Off-Study” Follow-up of Non-incident Lung Cancer Cases, Studies RON009393, RVN008993, and RHN009193) | 298 |
| Table 20-18. | Mortality Comparisons Across Treatment Groups - All Cause through December 31, 1997 (Intent-to-treat) | 299 |

| | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| Table 20-19. Mortality Comparisons Across Treatment Groups - All Cause through December 31, 1998 (Intent-to-treat)..... | 300 |
| Table 20-20. Mortality Comparisons Across Treatment Groups - Any Cancer Listed on the Death Certificate through December 31, 1997 (Intent-to-treat)..... | 301 |
| Table 20-21. Mortality Comparisons Across Treatment Groups - Lung Cancer Listed on the Death Certificate through December 31, 1997 (Intent-to-treat)..... | 302 |
| Table 20-22. Accountability of the 42 Patients with Lung Cancer Reported in the Clinical Database..... | 303 |
| Table 20-23. Analysis of Lung Cancer Mortality through 1997 in Current or Previous Smokers..... | 303 |
| Table 20-24. Mortality Comparisons Across Treatment Groups - Lung Cancer Listed on the Death Certificate Through December 31, 1997 Among Patients Without a Diagnosis of Lung Cancer, according to the Clinical Database (Intent-to-treat)..... | 304 |
| Table 21-1. The Innovation (Desired Risk Mitigation Behavior) | 320 |
| Table 21-2. Communication Channels | 322 |
| Table 21-3. Time and the Adoption Curve | 323 |
| Table 21-4. The Social System | 325 |
| Table 22-1. Components of the Proposed Risk Minimization Program for Product C in the EU. | 336 |
| Table 22-2. Evaluation Dimensions, Quantitative and Qualitative Measures, and Corresponding Data Sources for the Mixed Methods Evaluation of the RM Program for Product C Using the RE-AIM QuEST Framework..... | 338 |
| Index..... | 361 |

Author Acknowledgments

RAPS and lead editor, J. Michael Sprafka, MPH, PhD, thank the following subject matter experts for sharing their experience and knowledge and volunteering their time to contribute to this third edition of *Risk Management Principles for Devices and Pharmaceuticals*.

Nayan Achayara, MBBS,
MRCP, MFPM
Chapter 1

Jessica D. Albano, PhD, MPH
VP, Epidemiology & Analytics
Syneos Health
Chapter 14

Krishna Bahadursingh, MD,
FRCS, MBA, LLB, FFPM
Head of WorldWide Patient
Safety-Japan
Bristol Myers Squibb

Judy Bingham, MHA, GAICD
Executive Director
Easington Pty Ltd
Chapter 4

Mariette Boerstoele-Streefland,
MD, MSc, MBA
Chief Safety Officer, SVP
Patient Safety
AstraZeneca
Chapter 16

Brian Buysse, PhD
Senior Director, Epidemiology
Syneos Health
Chapter 14

Jemma Contreras, PhD
Advisory Group Lead, R&D
Consulting
Syneos Health
Chapter 23

Lindsay Crampton, BSc
Advisory Group Lead, Risk
& Program Management,
Consulting
Syneos Health
Chapter 23

George Cusatis MS, RAC
Sr. Regulatory Affairs Manager
Medtronic
Chapter 3

Karin de Haart, MSc
Product Strategy Lead
IQVIA
Chapter 13

Bruce R. DeMark, PhD
Retired Research Fellow
Procter & Gamble
Pharmaceuticals
Chapter 20

Debashish Dey, MD, PhD,
MPH
Vice President & Head, Drug
Safety & Pharmacovigilance
Intellia Therapeutics

Bernadette Dwan, BSc,
Mpharm, MPSI
Product Strategy Lead
IQVIA
Chapter 13

Michael Engwall, DVM, PhD,
DSP
Chapter 6

Sara Ephross, PhD
Senior Director, Epidemiology
Syneos Health
Chapter 14

Matthew Francis, MS, PhD
Epidemiologist
Procter and Gamble
Chapter 10

Angie Graves, MBA,
MLS(ASCP)
Senior Director, Business
Operations, Real World &
Late Phase
Syneos Health
Chapter 14

Mark Heinemann, BSc
Associate Director, Regulatory
Advice & Delivery
Syneos Health France SARL
Chapter 12